SKP1: A novel target for prognosis predicting and precise treatment in human cancers

Background: Prior research has demonstrated the intimate connection between cancer and S-phase kinase associated protein 1 (SKP1). Nevertheless, how SKP1 manifests in pan-cancer has not yet been fully clarified. Methods The current study aimed to completely examine the expression and prognosis prediction abilities of SKP1 in pan-cancer, utilizing a total of 11123 samples from 33 different forms of cancer. We also investigated the relationship between SKP1 expression and immunological microenvironment and genomic heterogeneity. Besides, gene set enrichment analysis (GSEA) provided insight into potential SKP1 involvement pathways in pan-cancer. Results SKP1 had various expression levels in different tissues and tumors. Its expression level was correlated with immune check point genes, mismatch repair genes, and some DNA methyltransferases. Furthermore, it was discovered that SKP1 expression was linked to microsatellite instability, tumor mutational burden, and neoantigen counts, indicating the therapeutic utility of SKP1 in cancers. Furthermore, it was discovered that SKP1 could identify and predict prognosis in a number of cancers. The majority of mRNA and protein level datasets on stomach adenocarcinoma showed that tumors expressed higher levels of SKP1 than did non-tumor samples. Finally, MIR497HG/hsa-miR-942-5p-SKP1 might be the potential regulatory pathway in stomach adenocarcinoma. Conclusion SKP1 may act as a novel target for prognosis predicting in human cancers and promotes the precise treatment for patients.